It looks more like he played those guys, and won!
They're getting 5% a year on their convertible shares. The equity financing conversion for those shares was probably based on Cytodyn bailing out IncellDX so they probably won't even get stuck with near worthless IncellDX shares. The notes are due in 18 months (April 2022 - August 2022). Just think how much ROI they're missing out on by not being able to use that money by buying cheap Cytodyn shares right now. It's enough to make one smile.